Literature DB >> 21696947

Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer.

Cornelia A J Brouwer1, Aleida Postma, Judith M Vonk, Nynke Zwart, Maarten P van den Berg, Margreet Th E Bink-Boelkens, Wil V Dolsma, Andries J Smit, Elisabeth G E de Vries, W J E Tissing, Jourik A Gietema.   

Abstract

AIM: To assess systolic and diastolic function in adult childhood-cancer survivors (CCS) after treatment entailing potential cardiovascular toxicity.
METHODS: The study cohort consisted of 277 adult CCS (median age 28 [range 18-48]years), who had been treated with anthracyclines, platinum, and/or radiotherapy between 1976 and 1999, along with 130 healthy sibling controls. The assessments included echocardiography, baroreflex sensitivity measurement, and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP). Echocardiography measurements were shortening fraction (SF) (abnormal<29%) for systolic function and tissue velocity imaging of early diastole (TVI Et) (abnormal<8.00)cm/sec for diastolic function; systolic function was also assessed by the wall motion score index (WMSI).
RESULTS: At 18 (5-31)years post-treatment, the prevalence of both impaired SF and abnormal WMSI was increased in CCS compared to controls (p=0.003 and p<0.001, respectively). CCS also had an increased prevalence of diastolic dysfunction compared to the controls (12% versus 1%, p<0.001). Abnormal SF and/or abnormal diastolic function were found in 43% of CCS. NT-proBNP was higher in CCS and was associated to increased WMSI. Baroreflex sensitivity was lower in CCS and was associated with diastolic dysfunction. Systolic as well as diastolic dysfunction was associated with cumulative dose of anthracyclines and mediastinal irradiation.
CONCLUSION: After treatment with potential cardiovascular toxic therapies, the risk of systolic and diastolic dysfunction in CCS is considerable. Since these abnormalities, in particular diastolic dysfunction, are age related, the observed effects might be considered a sign of precocious cardiac ageing.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696947     DOI: 10.1016/j.ejca.2011.05.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

Review 1.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

2.  Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.

Authors:  Gregory T Armstrong; Vijaya M Joshi; Kirsten K Ness; Thomas H Marwick; Nan Zhang; DeoKumar Srivastava; Brian P Griffin; Richard A Grimm; James Thomas; Dermot Phelan; Patrick Collier; Kevin R Krull; Daniel A Mulrooney; Daniel M Green; Melissa M Hudson; Leslie L Robison; Juan Carlos Plana
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

3.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.

Authors:  Gregory T Armstrong; Kevin C Oeffinger; Yan Chen; Toana Kawashima; Yutaka Yasui; Wendy Leisenring; Marilyn Stovall; Eric J Chow; Charles A Sklar; Daniel A Mulrooney; Ann C Mertens; William Border; Jean-Bernard Durand; Leslie L Robison; Lillian R Meacham
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

4.  Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Authors:  Mohammad Abu Zaid; Wambui G Gathirua-Mwangi; Chunkit Fung; Patrick O Monahan; Omar El-Charif; Annalynn M Williams; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra K Althouse; Shirin Ardeshir-Rouhani-Fard; Paul C Dinh; Howard D Sesso; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

5.  Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Tara M Brinkman; Nicole J Ullrich; Nan Zhang; Daniel M Green; Lonnie K Zeltzer; Karen M Lommel; Pim Brouwers; Deo Kumar Srivastava; Neelam Jain; Leslie L Robison; Kevin R Krull
Journal:  J Cancer Surviv       Date:  2012-12-08       Impact factor: 4.442

6.  Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.

Authors:  Saro H Armenian; Luc Mertens; Cameron Slorach; Kalyanasundaram Venkataraman; Kristen Mascarenhas; Nitya Nathwani; F Lennie Wong; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2017-11-07       Impact factor: 6.860

Review 7.  The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.

Authors:  Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-12       Impact factor: 4.733

Review 8.  Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.

Authors:  Rejane F Dillenburg; Paul Nathan; Luc Mertens
Journal:  Eur J Pediatr       Date:  2013-01-30       Impact factor: 3.183

9.  Association of persistent tachycardia with early myocardial dysfunction in children undergoing allogeneic hematopoietic cell transplantation.

Authors:  Jason F Goldberg; Emily J Peters; Elizabeth A Tolley; Mazal N Hagler; Vijaya M Joshi; Shelby E Wallace; Simonne S Nouer; Gary S Beasley; Hugo R Martinez; Kaitlin A Ryan; Mohammed A Absi; Jenny R Strelsin; Jeffrey A Towbin; Brandon M Triplett
Journal:  Bone Marrow Transplant       Date:  2021-05-20       Impact factor: 5.483

10.  Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.

Authors:  Robin L Jones; Andrew J Wagner; Akira Kawai; Kazuo Tamura; Ashwin Shahir; Brian A Van Tine; Javier Martín-Broto; Patrick M Peterson; Jennifer Wright; William D Tap
Journal:  Clin Cancer Res       Date:  2021-02-25       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.